A Study of HS-20094 Evaluating Weight Loss in Obese and Overweight Chinese Subjects

A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of HS-20094 in Overweight and Obese Subjects

This is a study of HS-20094 in participants with overweight and obesity. The main purpose is to learn more about how HS-20094 affects body weight. The study period including 4-12 weeks dose titration and 12-20 weeks maintain treatment and 6 weeks follow up.

Study Overview

• Status: Recruiting
• Conditions: Overweight and Obesity
• Intervention / Treatment: Drug: Placebo; Drug: HS-20094

Detailed Description

This is a phase 2, double-blind, randomised, placebo-controlled trial to assess the efficacy of HS-20094 in Chinese subjects with overweight or obesity. We enrolled adults (aged 18-65 years, both inclusive) with overweight (body-mass index [BMI] ≥24 kg/m2) accompanied by at least one obesity-related comorbidity or obesity (BMI ≥28 kg/m2) from over 10 hospitals in China. Eligible participants were randomly assigned (4:1) within each cohort by using an interactive web-response system to receive once-weekly subcutaneous HS-20094 or placebo for 24 weeks in one of the 4 cohorts below：the 5 mg cohort (5 mg weeks 1-24) ，the 10 mg cohort（5 mg weeks 1-4，10 mg weeks 5-24），the 15 mg cohort（5 mg weeks 1-4，10 mg weeks 5-8,15 mg weeks 9-24），the 20 mg cohort（5 mg weeks 1-4，10 mg weeks 5-8，15 mg weeks 9-12，20 mg weeks 13-24）. The participants, investigators, study site personnel involved in treating and assessing participants in each cohort and sponsor personnel were masked to treatment allocation. The primary endpoints were the percent change in bodyweight from baseline and bodyweight reduction of 5% or higher. The secondary outcomes included the change from baseline to week 24 in waist circumference and BMI.

• Study Type: Interventional
• Enrollment (Estimated): 200
• Phase: Phase 2

Contacts and Locations

Study Locations

• China
  • Heilongjiang
    • Harbin, Heilongjiang, China, 150001
      • Recruiting
      • The Fourth Affiliated Hospital of Harbin Medical University
      • Contact: Zhifeng Cheng; Phone Number: 010-66110802; Email: hydsyczf@126.com
    • Harbin, Heilongjiang, China, 100044
      • Recruiting
      • The Fourth Affiliated Hospital of Harbin Medical University
      • Contact: Zhifeng Cheng, PhD; Phone Number: 010-66110802; Email: hydsyczf@126.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Male or female subjects,18-65 years of age at the time of signing informed consent.
2. BMI≥28.0kg/m2 or 24≤BMI<28.0 kg/ m2 with at least 1 weight-related comorbidity at screening visit.
3. Diet and exercise control for at least 3 months before screening visit,and less than 5 kg self-reported change within the last 3 months.

Exclusion Criteria:

• 1. Presence of-clinically significant lab or ECG results that may affect the evaluation of the efficacy or safety of the study drug at screening visit.

  2. poor-controlled hypertension. 3. PHQ-9 score≥15. 4. Medical history or illness that affects your weight. 5. Use of any medication or treatment that may have caused significant weight change within 3 months.

  6. History of bariatric surgery. 7. History of diabetes. 8. Acute infection, acute trauma, or medium to large surgery within 1 month prior to screening.

  9. History of acute cardiovascular and cerebrovascular diseases within 6 months prior to screening.

  10. Any organ-system malignancies developed within 5 years except for cured local basal cell cancer of the skin and in-situ cancer of the cervix.

  11. Confirmed or suspected depression, bipolar disorder, suicidal tendencies, schizophrenia, or other serious mental illness.

  12. History of alcohol and/or substance abuse or drug abuse within 1 year prior to screening.

  13. Participation in other clinical trials for any weight-loss indication within 3 months prior to screening, or participation in other clinical trials for any drug or medical device within 1 month prior to screening.

  14. Known or suspected hypersensitivity to trial product(s)or related products. 15. Female who is pregnant,breast-feeding or intends to become pregnant or is of childbearing potential and not using an adequate contraceptive method.

  16. Researchers and relevant staff of the research Centre or other people directly involved in the implementation of the programme,and their immediate family members.

  17. In the judgment of the investigator,there are circumstances that affect the safety of the subject or any other interference with the evaluation of the test results.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: HS-20094 5mg; Drug: HS-20094 administered subcutaneously (SC) once a week. Drug: Placebo administered subcutaneously (SC) once a week.	Drug: Placebo; Administered SC; Other Names: Placebo injection; Drug: HS-20094; Administered SC; Other Names: HS-20094 injection
Experimental: HS-20094 10mg; Drug: HS-20094 administered subcutaneously (SC) once a week. Drug: Placebo administered subcutaneously (SC) once a week.	Drug: Placebo; Administered SC; Other Names: Placebo injection; Drug: HS-20094; Administered SC; Other Names: HS-20094 injection
Experimental: HS-20094 15mg; Drug: HS-20094 administered subcutaneously (SC) once a week. Drug: Placebo administered subcutaneously (SC) once a week.	Drug: Placebo; Administered SC; Other Names: Placebo injection; Drug: HS-20094; Administered SC; Other Names: HS-20094 injection
Experimental: HS-20094 20mg; Drug: HS-20094 administered subcutaneously (SC) once a week. Drug: Placebo administered subcutaneously (SC) once a week.	Drug: Placebo; Administered SC; Other Names: Placebo injection; Drug: HS-20094; Administered SC; Other Names: HS-20094 injection

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percent Change from Baseline in Body Weight	Percent Change from Baseline in Body Weight	From Week 0 to Week 24

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of AEs During the Trial	Safety	From Week 0 to Week 24
Change from Baseline in Patient Health Questionnaire-9 (PHQ-9)		From Week 0 to Week 24
Change from Baseline in Columbia Suicide Severity Rating scale ( C-SSRS)		From Week 0 to Week 24
12-lead electrocardiogram (ECG) parameters: PR, R-R, QRS and QTcF (average)		From Week 0 to Week 24
Change from baseline in waist circumference after 24 weeks of treatment		From Week 0 to Week 24
Change from baseline in BMI after 24 weeks of treatment		From Week 0 to Week 24
Change from baseline in blood pressure after 24 weeks of treatment		From Week 0 to Week 24
Change from baseline in total cholesterol after 24 weeks of treatment		From Week 0 to Week 24
Change from baseline in fasting plasma glucose(FPG)after 24 weeks of treatment		From Week 0 to Week 24

Collaborators and Investigators

• Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): October 16, 2023
• Primary Completion (Estimated): August 30, 2024
• Study Completion (Estimated): October 16, 2024

Study Registration Dates

• First Submitted: October 17, 2023
• First Submitted That Met QC Criteria: November 3, 2023
• First Posted (Actual): November 7, 2023

Study Record Updates

• Last Update Posted (Actual): November 7, 2023
• Last Update Submitted That Met QC Criteria: November 3, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Overnutrition; Nutrition Disorders; Body Weight; Overweight
• Other Study ID Numbers: HS-20094-202

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No